(function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){ (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o), m=s.getElementsByTagName(o)[0];a.async=1;a.data-privacy-src=g;m.parentNode.insertBefore(a,m) })(window,document,'script','//www.google-analytics.com/analytics.js','ga'); ga('create', 'UA-1666707-3', 'auto'); ga('send', 'pageview');

Blog

Press Releases, Latest News, Updates

International Conference on Counterfeit Medical Products

Basel (Switzerland), 16.04.2010 - More than 140 participants, senior officials from health, law enforcement and judicial authorities from around 40 states, international organisations and institutions from around the world came together on

By |2020-04-01T12:48:37+01:00April 30th, 2010|Regulatory Affairs|0 Comments

Second annual Conference on Pharmaceutical Risk-Sharing & Value-based Pricing and Reimbursement Models

Bratislava, 15-16 th April 2010 Not being a specialist in the area of Risk-Sharing & Value-based Pricing this event was an excellent introduction for me. Meeting P&R experts from some

By |2020-04-01T12:48:37+01:00April 29th, 2010|Pricing and Reimbursment|0 Comments

Introduction of Braille Script for Pharmaceuticals in Ukraine

20.05.2009 was introduced an amendment to the law of Ukraine “On medicines” (? 124/96?? of 4.04.96) which orders to use Braille script on packages. Changes came into force until 01.01.10.

By |2020-04-01T12:49:08+01:00April 23rd, 2010|Regulatory Affairs|0 Comments

Market dynamics and the changing healthcare and regulatory environment

This report provides a comprehensive examination of the clinical trial landscape in emerging countries, with specific focus on China, India, Central and Eastern Europe and Latin America. It identifies the

By |2020-04-01T12:49:08+01:00January 21st, 2010|Clinical trials|0 Comments

Variations to the Terms of Medicinal Products Registered in Albania

This file will explain you how to apply for variation to the trems of medical products and in short a procedure for revocation of marketing authorisation. In the Annex 1

By |2020-04-01T12:49:08+01:00August 11th, 2009|Regulatory Affairs|0 Comments
Go to Top